Gemtuzumab Ozogamicin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Gemtuzumab Ozogamicin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
99
Registered trials
75
Result records
18
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Gemtuzumab Ozogamicin can convert its Antibody drug conjugate (ADC) profile and CD33 x DNA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Gemtuzumab Ozogamicin (query alias: gemtuzumab ozogamicin) |
|---|---|
| Modality / target | Antibody drug conjugate (ADC); CD33 x DNA; CD33 inhibitors, DNA inhibitors |
| Highest global status | Approved |
| Originator | Pfizer Inc. |
| Active developers | Pfizer Europe MA EEIG, Pfizer Inc., Pfizer Japan, Inc. |
The MCP disease footprint includes CD33-positive Acute Myeloid Leukemia, Acute Myeloid Leukemia, Residual Neoplasm. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05955261 | Phase 2 | Suspended | 70 | Minimal residual disease (MRD)-negativity rate |
| NCT05599360 | Phase 2 | Active, not recruiting | 20 | Response rate for low/intermediate risk AML after induction with Vyxeos |
| NCT06448013 | Phase 1 | Recruiting | 22 | Safety and adverse events (AEs) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Contemporary Epidemiology of Veno-Occlusive Disease/Sinusoidal Obstructive Syndrome (VOD) in Pediatric Patients Transplanted for Acute Leukemia: Association with Antibody-Drug Conjugate Medications
Not Applicable; n=542; evaluation: Positive. Reported fields: VOD(severe) = 10.0 % ; VOD(severe) = 26.0 %
Optimization of induction chemotherapy in pediatric patients with Acute Myeloid Leukemia: Real-world evidence to support removal of etoposide from induction 1
Not Applicable; n=795; evaluation: Positive. Reported fields: EFS(2-year) = 56.0 % ; EFS(2-year) = 57.0 %
GO-FIRST: REAL-WORLD DATA OF FRONT LINE GEMTUZUMAB OZOGAMICIN IN INTERMEDIATE AND FAVORABLE RISK AML PATIENTS IN A MULTICENTER RETROSPECTIVE CHART REVIEW
Not Applicable; n=84; evaluation: not stated. Reported fields: Adverse Event: VOD following SCT = 1 had VOD following SCT
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Gemtuzumab Ozogamicin addresses CD33-positive Acute Myeloid Leukemia, Acute Myeloid Leukemia, Residual Neoplasm. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Antibody drug conjugate (ADC)—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 18 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CD33 x DNA records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-10-11 | After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen | Not disclosed | Financial terms not disclosed |
| 2023-11-06 | Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb | Phase 1 | US$100.0M upfront; US$180.0M stated total |
| 2023-02-18 | Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute to Further Enhance Clinical and Non-clinical Development of Actimab-A for the Treatment of Acute Myeloid Leukemia and Other Hematologic Malignancies | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- CLDN18.2 assay, cutoff, and intratumoral heterogeneity
- Payload-related toxicity and dose intensity
- Crowding from antibodies, bispecifics, CAR-Ts, and competing ADCs
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
